tiprankstipranks
Medicus Pharma Eyes Veterinary Market with FDA Designation
Company Announcements

Medicus Pharma Eyes Veterinary Market with FDA Designation

Story Highlights

Medicus Pharma Ltd (TSE:MDCX) has released an update.

Pick the best stocks and maximize your portfolio:

Medicus Pharma Ltd. has received a Minor Use in Major Species Designation from the FDA for their innovative Doxorubicin-containing microneedle array patch aimed at treating squamous cell carcinoma in horses. This designation could give Medicus a competitive edge with exclusive marketing rights for seven years if the product is approved. The company’s progress signals a promising future in the veterinary pharmaceutical market, potentially leading to a commercially viable product by 2026.

For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMedicus Pharma initiated with a Buy at Maxim
TheFlyMedicus Pharma announcs its INAD received MUMS from U.S. FDA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App